A Phase II Pilot Study of Glivec (imatinib mesylate formerly known as STI571) Combined with Induction Chemotherapy in Blast-Phase Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, to evaluate safety and improve remission rate.

DOI number 10.58109/24a2-eg26
Publisher Australasian Leukaemia and Lymphoma Group (ALLG)

Australasian Leukaemia and Lymphoma Group (ALLG)

Kenneth Bradstock (Westmead Hospital)

Date Made Available 2023
Dataset Individual participant data (IPD) in aggregate form
Description of Dataset

Dataset includes:

  • Data for 41 patients with blast phase CML, utilising Glivec and monitoring remission statusDemographic data
  • Diagnostic data
  • Treatment data
  • Outcome data

Australasian Leukaemia and Lymphoma Group (ALLG)

Subject (ANZSRC Category)


ANZCTR Reference ACTRN12605000072617
Dataset Access

Access can be requested via the Health Data Australia catalogue. Search for the ACTRN number in the catalogue to find datasets associated with this trial or email enquiries to info@allg.org.au